SAN DIEGO (AP) — SAN DIEGO (AP) — Fate Therapeutics Inc. (FATE) on Tuesday reported a loss of $34.1 million in its second quarter.
The San Diego-based company said it had a loss of 29 cents per share.
The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 35 cents per share.
The clinical-stage biotech company that develops stem cell treatments posted revenue of $1.9 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $656,000.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FATE at https://www.zacks.com/ap/FATE
View Comments
Fate Therapeutics: Q2 Earnings Snapshot
Published 2 months ago
Aug 12, 2025 at 8:30 PM
Neutral
Auto